Swiss Life Sciences Stock News

If you are wondering whether Partners Group Holding is attractively priced today, you are not alone. Many investors are trying to work out if the current share price reflects its long term potential. The stock closed at CHF 811.60, with returns of 1% decline over the last 7 days, 14.7% decline over 30 days, 21.2% decline year to date, and 35.9% decline over 1 year, while the 3 year return stands at 21.3% and the 5 year return at 15.6% decline. These moves have played out against a steady...

PolyPeptide Group (SWX:PPGN) has just posted its FY 2025 first half results, reporting revenue of €167.1 million and a loss per share of €0.80, alongside net income excluding extra items of a €26.5 million loss. Over recent periods the company’s revenue moved from €135.0 million in the first half of 2024 to €201.7 million in the second half of 2024 and then to €167.1 million in the first half of 2025. EPS over the same periods shifted from a €0.35 loss to a €0.24 loss and then to a €0.80...

Earlier this month, ALSO Holding AG’s Board of Directors approved a share repurchase program of up to 9.74% of its capital for €120 million, aiming to use the treasury shares for acquisitions, liquidity, and long‑term management incentives. Around the same time, the company launched an AI Competence Center to help its partner network sell AI solutions, underscoring its focus on Microsoft 365 Copilot and the broader European AI ecosystem. We will now examine how the launch of the AI...

Bachem Holding (SWX:BANB) is back in focus after reporting strong 2025 sales and profitability, outlining heavy capacity investments for 2026, and pairing that operational push with a higher proposed dividend. See our latest analysis for Bachem Holding. Over the past year, Bachem Holding’s share price has shown mixed momentum, with a 13.55% 90 day share price return and a 14.49% 1 year total shareholder return, in contrast with weaker 3 and 5 year total shareholder returns. This suggests that...

Why Medacta Group’s latest earnings matter for shareholders Medacta Group (SWX:MOVE) has just reported its 2025 results, with revenue of €684 million, EBITDA margin at 29%, net profit up 31% year over year, and a proposed dividend of CHF 1.10 per share, almost 60% higher. See our latest analysis for Medacta Group. At a share price of CHF155.8, Medacta’s 5.7% 1 month share price return sits against a modestly positive 3 month move of 3.0% and a much stronger 1 year total shareholder return of...

Why ABB stock is drawing fresh attention ABB (SWX:ABBN) is back on radar after a recent pullback, with the share price around CHF 66.44 and mixed short term returns that contrast with its past year and multi year performance. With annual revenue of about $33.2b and net income near $4.56b, investors are weighing how this industrial and automation group’s current valuation lines up with its earnings power and recent financial profile. See our latest analysis for ABB. The latest pullback,...

Autoneum Holding (SWX:AUTN) has reported its FY 2025 first half with revenue of CHF 1.2b and basic EPS of CHF 5.16, supported by trailing twelve month revenue of CHF 2.3b and EPS of CHF 10.34 that sit against a year ago revenue base of CHF 2.3b and EPS of CHF 8.97. The company has seen revenue move between CHF 1.2b and CHF 1.1b across the last two reported half years while EPS has ranged from CHF 4.11 to CHF 5.16. Trailing net income of CHF 60.0m frames a modest net margin profile that keeps...

Swiss Life Holding (SWX:SLHN) has released its FY 2025 scorecard with first-half revenue of CHF 5.7b and basic EPS of CHF 20.57, set against trailing 12-month revenue of CHF 11.6b and EPS of CHF 41.58 that follow a period where earnings rose 9% year on year and margins moved to 10.1% from 9.4%. Over the last few reporting halves, revenue has moved from CHF 6.1b and EPS of CHF 21.40 in the first half of 2024, to CHF 5.9b and EPS of CHF 21.01 in the second half of 2024, to the latest CHF 5.7b...

Interroll Holding (SWX:INRN) has opened FY 2025 with first half revenue of CHF 247.7 million and basic EPS of CHF 25.46, setting the stage against a trailing twelve month picture that includes CHF 527.4 million in revenue and CHF 72.00 in EPS. The company has seen revenue move from CHF 247.4 million in the first half of 2024 to CHF 279.7 million in the second half of 2024, while basic EPS shifted from CHF 28.93 to CHF 46.61 over the same period, giving investors a clear line of sight into how...

Amrize (SWX:AMRZ) is drawing fresh attention after launching its EVERtect high performance concrete range at CONEXPO CON/AGG, pairing this product rollout with recent insider and institutional share purchases. See our latest analysis for Amrize. Despite the EVERtect launch, insider buying and the upcoming AGM, Amrize’s recent momentum has been soft, with a 30-day share price return of a 4.62% decline and a year-to-date share price return of a 2.20% decline from CHF43.52. If this concrete...

If you are wondering whether Cosmo Pharmaceuticals at around CHF 87.00 is still offering value after a solid run, this article walks through what the current price might be implying about the company. The stock has pulled back recently, with a 19.0% decline over the last 7 days and a 24.6% decline over the last 30 days, even though the 1 year return sits at 66.3% and the 3 year return at 70.4%. These moves come against a backdrop where investors are reassessing prior gains and weighing Cosmo...

In early March 2026, Giatec Scientific announced a commercial partnership with Sika to integrate Giatec’s AI-powered concrete sensors, software, and data tools into Sika’s global concrete product offering, supporting the Fast Forward program that targets an incremental EBITDA contribution of CHF 150.00 to 200.00 million by 2028. This move expands Sika’s digital capabilities across the concrete value chain, giving its customers access to real-time, AI-driven mix optimization and monitoring...

UBS Group (SWX:UBSG) is in focus after recent share price weakness, with the stock showing negative returns over the past month and past 3 months, prompting investors to reassess its long term performance profile. See our latest analysis for UBS Group. At a share price of CHF29.51, UBS Group’s recent 30 day share price return of 11.91% and year to date share price return of 22.69% contrast with a 1 year total shareholder return of 8.57%, and the stronger 3 year and 5 year total shareholder...

Accelleron Industries (SWX:ACLN) is back in focus after reporting robust 2025 revenue and earnings, pairing a higher dividend with a CHF 100 million buyback plan and guidance for continued profitable growth into 2026. See our latest analysis for Accelleron Industries. The strong 2025 results, higher dividend, and CHF 100 million buyback have coincided with a sharp shift in sentiment. A 1-day share price return of 11.76% has helped lift the year-to-date share price return to 16.96%, while the...

Comet Holding (SWX:COTN) is in focus after its latest full year earnings showed higher sales alongside weaker profitability, paired with a proposed dividend cut and mixed guidance that coincided with a sharp share price drop. See our latest analysis for Comet Holding. The earnings miss, dividend cut proposal and reference to valuation compression have quickly fed into sentiment. The share price at CHF249.4 now carries a 7 day share price return of 12.12% and a 30 day share price return of...

What triggered the latest move in PolyPeptide Group? PolyPeptide Group (SWX:PPGN) released full-year 2025 results in line with expectations and paired them with 2026 guidance that indicates higher revenue and margins, along with an upcoming CFO change. See our latest analysis for PolyPeptide Group. The upbeat 2025 results and 2026 guidance have come alongside a sharp shift in sentiment, with an 8.78% 1 day share price return and a year to date share price return of 11.04%. The 1 year total...

Novartis (SWX:NOVN) is back on investor radars after recent share price moves, with the stock showing mixed short term performance but stronger returns over the past 3 months and year. See our latest analysis for Novartis. The recent 1 week and 1 day share price declines sit against a stronger 90 day share price return of 14.5% and a 1 year total shareholder return of 28.5%. This suggests momentum has been building over a longer horizon despite near term softness. If Novartis has caught your...

BKW (SWX:BKW) has put out its FY 2025 numbers with first half revenue of CHF 2.1b and basic EPS of CHF 3.54. This sets the tone for a year in which trailing twelve month revenue sits at CHF 4.5b and EPS at CHF 6.77. Over the last few reporting periods, the company has seen revenue move from CHF 2.2b and EPS of CHF 6.62 in 1H 2024 to CHF 2.4b and EPS of CHF 5.18 in 2H 2024, before landing at the latest 1H 2025 figures. This leaves investors focused on how the compression in net profit margins...

Vetropack Holding (SWX:VETN) has just posted its FY 2025 numbers, with first half revenue at CHF 412.7 million and EPS of CHF 0.49, while trailing 12 month revenue sits at CHF 792.1 million and EPS at CHF 0.19 after a period marked by a CHF 17.1 million one off loss and a 0.5% net margin in the inputs. The company has seen reported revenue move from CHF 444.9 million in the first half of 2024 to CHF 412.7 million in the first half of 2025, with EPS shifting from CHF 0.47 to CHF 0.49 over the...

Geberit (SWX:GEBN) has wrapped up FY 2025 with fourth quarter revenue of CHF 715.4 million and Basic EPS of CHF 3.14, alongside trailing twelve month revenue of CHF 3.2 billion and EPS of CHF 18.15 that frame the full year earnings picture. Over recent periods, the company has seen quarterly revenue move from CHF 685.3 million in Q4 2024 to CHF 715.4 million in Q4 2025, while Basic EPS in those fourth quarters shifted from about CHF 2.93 to CHF 3.14. This gives investors a clear read on top...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has wrapped up FY 2025 with second half revenue of CHF3.6b and basic EPS of CHF2,368.83, alongside net income of CHF538.3m, setting the tone for how investors will read the latest full year story. Over the past few periods, the company has seen revenue move from CHF3.3b in 2H 2024 to CHF3.6b in 2H 2025, while trailing twelve month basic EPS tracked at CHF3,163.95 and net income at CHF727.2m. This gives a clearer view of the earnings run rate...

Kardex Holding (SWX:KARN) has just posted its FY 2025 numbers with first half revenue of €415.7 million, basic EPS of €4.69 and net income of €36.2 million, while the trailing twelve months show revenue of €850.4 million, EPS of €5.39 and net income of €41.6 million. The company has seen revenue move from €369.7 million and EPS of €4.95 in 2024 H1 to €421.5 million and EPS of €5.50 in 2024 H2, setting up FY 2025 results against a backdrop of shifting profitability and mixed margin signals...

Huber+Suhner (SWX:HUBN) has just posted its FY 2025 first half results, logging revenue of CHF 445.9 million and basic EPS of CHF 1.97, compared with revenue of CHF 430.6 million and EPS of CHF 1.87 in the first half of FY 2024. Over the same period, trailing twelve month revenue has been in the range of CHF 864.1 million to CHF 909.2 million, while trailing EPS moved from CHF 3.87 to CHF 4.03. This provides investors with a relatively steady view of earnings power and a margin profile that...

Partners Group Holding (SWX:PGHN) has drawn fresh attention after reporting full year 2025 earnings and declaring an annual dividend of CHF 46.00 per share, with payment scheduled for late May 2026. See our latest analysis for Partners Group Holding. Even with the strong 2025 results and the CHF 46.00 dividend announcement, the share price has been under pressure, with a 30 day share price return of 18.15% and a 1 year total shareholder return of 34.06%. The 3 year total shareholder return of...